<div id="readability-page-1"><p>Nippon Life Global Investors Americas Inc. boosted its stake in shares of  AbbVie Inc. (NYSE:ABBV - Free Report) by 3.3% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 44,680 shares of the company's stock after buying an additional 1,420 shares during the quarter. Nippon Life Global Investors Americas Inc.'s holdings in AbbVie were worth $9,361,000 as of its most recent SEC filing.</p><ul><li>As the Market Rotates, This Healthcare ETF Is Leading the Way</li></ul><p>Several other hedge funds have also added to or reduced their stakes in ABBV. Narus Financial Partners LLC lifted its stake in  AbbVie by 25.3% in the first quarter. Narus Financial Partners LLC now owns 1,988 shares of the company's stock valued at $417,000 after purchasing an additional 401 shares during the last quarter.  Highland Capital Management LLC lifted its stake in  AbbVie by 6.3% in the first quarter. Highland Capital Management LLC now owns 46,853 shares of the company's stock valued at $9,817,000 after purchasing an additional 2,792 shares during the last quarter.  Weaver Capital Management LLC lifted its stake in  AbbVie by 3.9% in the first quarter. Weaver Capital Management LLC now owns 8,240 shares of the company's stock valued at $1,727,000 after purchasing an additional 310 shares during the last quarter.  North Star Asset Management Inc. lifted its stake in  AbbVie by 0.5% in the first quarter. North Star Asset Management Inc. now owns 161,320 shares of the company's stock valued at $33,800,000 after purchasing an additional 756 shares during the last quarter.  Finally, Alpine Bank Wealth Management purchased a new position in  AbbVie in the first quarter valued at approximately $3,879,000. Institutional investors own  70.23% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><p>Several research firms recently commented on ABBV. Daiwa Capital Markets upgraded AbbVie from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and set a $214.00 price objective on the stock in a research note on Thursday, August 7th. Bank of America upped their price objective on AbbVie to $204.00 and gave the company a &#34;hold&#34; rating in a research note on Monday, June 9th. Citigroup upped their price objective on AbbVie to $205.00 and gave the company a &#34;hold&#34; rating in a research note on Wednesday, June 11th. BNP Paribas upgraded AbbVie to a &#34;hold&#34; rating in a research report on Thursday, May 8th. Finally, Piper Sandler started coverage on AbbVie in a research report on Tuesday, August 12th. They set an &#34;overweight&#34; rating and a $231.00 target price on the stock. Four analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued  a Hold rating to the company's stock. According to MarketBeat, AbbVie presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $214.95.</p><ul><li>AbbVie Stock Eyes Breakout as Pipeline and Profits Grow</li></ul><p><b>Get Our Latest Stock Report on ABBV</b></p><h2>AbbVie Trading Up 0.4%</h2><p>AbbVie stock opened at $212.77 on Friday. The stock has a market cap of $375.87 billion, a P/E ratio of 101.32, a PEG ratio of 1.36 and a beta of 0.53. AbbVie Inc. has a fifty-two week low of $163.81 and a fifty-two week high of $218.66. The firm's fifty day moving average price is $197.13 and its 200-day moving average price is $194.04. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. </p><ul><li>3 Biotech Giants Gaining From U.S. Sales and Policy Shifts</li></ul><p>AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported $2.97 earnings per share for the quarter, missing the consensus estimate of $3.24 by ($0.27). The firm had revenue of $15.42 billion during the quarter, compared to the consensus estimate of $14.93 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The company's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period in the previous year, the company posted $2.65 EPS.  Equities research analysts forecast that  AbbVie Inc. will post 12.31 earnings per share for the current fiscal year. </p><h2>AbbVie Dividend Announcement</h2><p>The company also recently declared a quarterly dividend, which was paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th were issued a $1.64 dividend. The ex-dividend date of this dividend was Tuesday, July 15th. This represents a $6.56 annualized dividend and a dividend yield of 3.1%. AbbVie's dividend payout ratio  is presently 312.38%. </p><h2>Insider Buying and Selling at AbbVie</h2><p>In other news, EVP Nicholas Donoghoe sold 13,295 shares of the company's stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total value of $2,639,190.45. Following the transaction, the executive vice president owned 58,247 shares of the company's stock, valued at approximately $11,562,611.97. This represents a 18.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Azita Saleki-Gerhardt sold 42,370 shares of the company's stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the completion of the transaction, the executive vice president directly owned 177,292 shares in the company, valued at approximately $35,178,278.64. The trade was a 19.29% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own  0.25% of the company's stock. </p><h2>AbbVie Profile</h2> (Free Report)<p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p><h2>See Also</h2><ul><li>Five stocks we like better than AbbVie</li><li>What is an Earnings Surprise?  </li><li>Why Marvell’s 19% Drop Could Be a Big Buy-the-Dip Opportunity</li><li>What Are Treasury Bonds?</li><li>Daqo New Energy: Solar Monopoly Launches $100M Buyback</li><li>Dividend Screener: How to Evaluate Dividend Stocks Before Buying</li><li>Affirm Crushes Earnings Expectations, Turns Bears into Believers</li></ul><p><strong>Want to see what other hedge funds are holding ABBV?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AbbVie Right Now?</h2><p>Before you consider AbbVie, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ABBV

<p>Nippon Life Global Investors Americas Inc. increased its stake in AbbVie Inc. by 3.3% in Q1, owning 44,680 shares valued at $9.36 million. Other hedge funds also adjusted their holdings in AbbVie. Analysts have upgraded AbbVie, with a consensus rating of "Moderate Buy" and an average target price of $214.95. AbbVie reported Q2 earnings of $2.97 per share, missing estimates, but revenue rose to $15.42 billion. The company declared a quarterly dividend of $1.64, yielding 3.1%.</p>

Nippon Life Global Investors Americas Inc. Raises Stake in AbbVie Inc. $ABBV